Experimental Testing of a Size-Exclusion Chromatography Method Used for Evaluation of Molecular Parameters of Equine Anti-Ebola Immunoglobulin

Haemorrhagic fever caused by the Ebola virus is a highly hazardous infectious disease with a mortality rate of 50– 90 %. Heterologous immunoglobulins with a high virus-neutralizing titer are an important element of the WHO-endorsed set of measures for emergency prevention and treatment of the disease. Specific activity of these products is largely determined by their fractional composition, and, in particular, by molecular mass distribution (MMD). The size-exclusion-high-performance liquid chromatography (SEC-HPLC) has traditionally been used for determination of the MMD of the target protein in human immunoglobulin-based products. The use of this method for evaluation of molecular parameters of heterologous immunoglobulin requires confirmation of its specificity, accuracy and precision, and establishment of the chromatographic system suitability criteria in the context of a new test object. The aim of the study was to test the applicability of the SEC-HPLC method to the assessment of molecular parameters of anti-Ebola immunoglobulin derived from horse serum. Materials and methods: three batches of purified equine anti-Ebola immunoglobulin were used in the study. Normal equine and human immunoglobulins of the IgG isotype were used as reference standards. The HPLC test procedures described in the European Pharmacopoeia 9.6 and State Pharmacopoeia of the Russian Federation, 14th ed., were used for determination of monomers and other immunoglobulin fractions. An Agilent 1260 Infinity (Agilent, USA) HPLC system with a diode array detector and an Agilent Bio SEC-3 HPLC column were used for quality evaluation of the tested products. Results: the resolution factor between IgG monomer and dimer peaks (1.69 and 2.10), and the chromatographic column efficiency (>2000) make it possible to use the SEC-HPLC system for evaluation of molecular parameters of heterologous immunoglobulin. The study demonstrated reproducibility of the test procedure. Conclusions: the study confirmed the applicability of the SEC-HPLC procedure for evaluation of molecular parameters of anti-Ebola immunoglobulin derived from horse serum. It demonstrated the compliance of the purified immunoglobulin to the national and international quality requirements in terms of «Molecular parameters».

1. Feldmann H, Geisbert TW. Ebola haemorrhagic fever. Lancet. 2011;377(9768):849–62. https://doi.org/10.1016/S0140-6736(10)60667-8

2. Dowall SD, Callan J, Zeltina A, Al-Abdulla I, Strecker T, Fehling SK, et al. Development of a cost-effective ovine polyclonal antibody-based product, EBOTAb, to treat Ebola virus infection. J Infect Dis. 2016;213(7):1124–33. https://doi.org/10.1093/infdis/jiv565

3. Borisevich IV, Krasnyanskiy VP, Mikhaylov VV, Potryvaeva NV, Gradoboev VN, Timan’kova GD, Karelov YuM. Development and production of immunoglobulin against Ebola. In: The study and prevention of especially dangerous viral infections. Koltsovo; 1993. P. 44 (In Russ.)

4. Maruyama T, Rodriguez LL, Jahrling PB, Sanchez A, Khan AS, Nichol ST, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 1999;73(7):6024–30.

5. Mikhaylov VV, Borisevich IV, Timan’kova GD, Krasnyanskiy VP, Potryvaeva NV, Lebedinskaya EV, Chernikova NK. Preparation containing immunoglobulin against Ebola fever from horse blood serum and liquid (Ebola immunoglobulin). Patent of the Russian Federation No. 2130318; 1999 (In Russ.)

6. Borisevich IV, Chernikova NK, Markov VI, Krasnianskiy VP, Borisevich SV, Rozhdestvenskiy EV. An experience in the clinical use of specific immunoglobulin from horse blood serum for prophylaxis of Ebola haemorrhagic fever. Voprosy virusologii = Problems of Virology. 2017;62(1):25–9 (In Russ.)

7. Fernandes A, Kaundinya JO, Daftary G, Saxena L, Banerjee S, Pattnaik P. Chromatographic purification of equine immunoglobulin G F(ab)2 from plasma. J Chromatogr B Analyt Technol Biomed Life Sci. 2008;876(1):109–15. https://doi.org/10.1016/j.jchromb.2008.10.030

8. Popova AYu, Demina YuV, Smolenskiy VYu, Gordeev EV, Rozhdestvenskiy EV, Krasnyanskiy VP, et al. Method for producing liquid immunoglobulin against Ebola fever from horse blood serum. Patent of the Russian Federation No. 2673546; 2018 (In Russ.)